| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e2f19e2be4e1e36ec29b191e3e1be2a0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_764c37797762f79bedf08832dbf3a65a |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C405-0041 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D307-77
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-335
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-343
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C405-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D317-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-12 |
| filingDate |
2009-04-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_512a07769c8ada79f2d8f33cce27f2c1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_60a07124e2ace159968f97b6216b1555 |
| publicationDate |
2009-10-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2009252685-A1 |
| titleOfInvention |
High penetration prodrug compositions of prostaglandins and related compounds |
| abstract |
The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of prostaglandins or prostaglandin analogs which are capable of crossing biological barriers with high penetration efficiency. The HPPs are capable of being converted to parent prostaglandins or prostaglandin analogs after crossing the biological barrier and thus can render treatments for the conditions that the parent prostaglandins or prostaglandin analogs can. Additionally, the HPPs are capable of reaching areas that parent prostaglandins or prostaglandin analogs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11246932-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9517218-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10632086-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9855231-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2693877-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2693877-A4 |
| priorityDate |
2006-10-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |